Welcome to our dedicated page for Neuropace news (Ticker: NPCE), a resource for investors and traders seeking the latest updates and insights on Neuropace stock.
NeuroPace Inc (NPCE) is a pioneering medical technology company developing brain-responsive neuromodulation systems for epilepsy treatment. This page serves as the definitive source for official company announcements, financial updates, and clinical progress reports.
Access timely updates on NPCE's innovative RNS System, including FDA regulatory milestones, partnership developments with leading epilepsy centers, and peer-reviewed clinical study results. Investors will find earnings reports and strategic initiatives, while healthcare professionals can track real-world treatment outcomes and technological refinements.
Our curated news collection features:
- Quarterly financial performance updates
- RNS System enhancement announcements
- Clinical trial data publications
- Regulatory clearance milestones
- Research collaborations with medical institutions
Bookmark this page for structured access to NPCE's evolving role in neurotechnology and epilepsy care innovation.
NeuroPace (Nasdaq: NPCE) filed a PMA supplement with the U.S. Food and Drug Administration on December 17, 2025, seeking to expand the RNS System indication to antiseizure‑medication (ASM) resistant idiopathic generalized epilepsy (IGE) with generalized tonic‑clonic (GTC) seizures.
The submission is supported by preliminary 18‑month NAUTILUS data showing a 77% median GTC seizure reduction and a favorable safety profile, and the RNS System has received Breakthrough Device Designation for this IGE indication. Under current FDA guidance, PMA supplements are typically reviewed in about 180 days, although actual review times may vary.
NeuroPace (Nasdaq: NPCE) reported preliminary 18-month results from the ongoing NAUTILUS1 trial of the RNS System in drug-resistant idiopathic generalized epilepsy (IGE) with generalized tonic-clonic (GTC) seizures.
Key results: a 77% median reduction in GTC seizures versus baseline at 18 months (p<0.001), rapid and sustained reductions in GTCs and seizure-free days, Clinical Global Impression of Change >80% among patients and physicians, and safety consistent with the established RNS System profile (p<0.0001). NeuroPace said it remains on track to submit a PMA supplement to the FDA to expand the RNS indication to IGE by year-end 2025.
NeuroPace (Nasdaq: NPCE) will spotlight clinical outcomes and AI tools for epilepsy at the 2025 American Epilepsy Society Annual Meeting in Atlanta (Dec 6–7, 2025).
Highlights include 18-month NAUTILUS safety and efficacy results for idiopathic generalized epilepsy, new Post-Approval Study analyses showing seizure reduction durability at three years+, demonstrations of next-generation NeuroPace AI and SeizureID, and the RNS System featured across 80+ scientific presentations and posters.
NeuroPace will host a Product Theater on Dec 7, 2025 2:30–3:30 PM and will be at Booth #125 for demos and tech suite sessions.
NeuroPace (NASDAQ: NPCE) announced Medicare reimbursement increases for the RNS System under the CY 2026 Physician Fee Schedule (PFS) and Outpatient Prospective Payment System (OPPS) final rules.
Key changes: PFS raises professional payments ~43% (+$530) for initial implant and ~45% (+$260) for replacements; OPPS reassigns RNS replacement CPT 61891 to the highest-paying neurostimulator APC, boosting average hospital Medicare reimbursement by 47% from $21,444 (CY 2025) to $31,526 effective January 1, 2026.
Company commentary notes these updates could better reflect provider resources, support neurosurgeon adoption and procedure growth, and provide a tailwind as replacement procedures grow as a business contributor.
NeuroPace (NASDAQ: NPCE) reported Q3 2025 revenue of $27.4M, up 30% year‑over‑year, with RNS System revenue of $22.6M (+31%). Gross margin was 77.4%. Net loss was $3.5M and loss from operations was $2.6M. Cash, cash equivalents and short‑term investments were $60.0M and long‑term borrowings were $58.7M as of Sept 30, 2025.
The company increased full‑year 2025 revenue guidance to $97M–$98M (growth 21%–23%) and raised gross margin guidance to 76%–77%. Operational updates include submitting Seizure ID to the FDA, a completed FDA pre‑submission for the NAUTILUS IGE study, and plans to submit a PMA supplement for IGE by year‑end 2025.
NeuroPace (Nasdaq: NPCE) will report third quarter 2025 financial results after market close on November 4, 2025. Management will host a webcast and conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET the same day.
Investors can listen via a live webcast at the events page or join by phone at +1 (800) 715-9871 using Conference ID 8467256. The webcast will be archived on the company investor relations site and will be available for replay for at least 90 days.
NeuroPace (Nasdaq: NPCE), a medical device company specializing in epilepsy treatment, has announced its participation in two upcoming healthcare conferences in September 2025. The management team will attend the Wells Fargo Healthcare Conference on September 3 in Boston for one-on-one investor meetings.
Additionally, the company will participate in a fireside chat at the Cantor Global Healthcare Conference on September 4 at 9:45am ET. The fireside chat will be available via live webcast, with a replay accessible through NeuroPace's investor website.
NeuroPace (NASDAQ: NPCE), a medical device company specializing in epilepsy treatment, reported strong Q2 2025 financial results. The company achieved record quarterly revenue of $23.5 million, representing a 22% year-over-year growth. Gross margin improved to 77.1%, up from 73.4% in Q2 2024.
The company increased its 2025 revenue guidance to $94-98 million (18-23% growth) and raised gross margin guidance to 75-76%. Key operational highlights include preliminary data from the NAUTILUS study for IGE therapy, showing a 79% median GTC seizure reduction at 12 months. NeuroPace also secured a new $75 million credit facility with MidCap Financial and maintained favorable CMS reimbursement status for RNS procedures.
NeuroPace (Nasdaq: NPCE) announced that the Centers for Medicare & Medicaid Services (CMS) has maintained the current Medicare Severity Diagnosis Related Group (MS-DRG) assignment for RNS® System procedures under MS-DRG 023 for FY 2026. This decision comes after CMS initially proposed reassigning epilepsy with neurostimulator cases to MS-DRG 020-022.
CEO Joel Becker welcomed the decision, highlighting its importance for hospitals providing RNS System treatment to Medicare beneficiaries. The company will continue collaborating with CMS on MS-DRG improvements and reimbursement policies to ensure broader access to their epilepsy treatment technology.
NeuroPace (NASDAQ: NPCE), a medical device company specializing in epilepsy treatment, has scheduled its second quarter 2025 financial results announcement for August 12, 2025 after market close.
The company will host a conference call at 1:30 PM PT / 4:30 PM ET on the same day. Investors can join via webcast or telephone, with the webcast being archived on NeuroPace's investor relations website for at least 90 days.
FAQ
What is the current stock price of Neuropace (NPCE)?
What is the market cap of Neuropace (NPCE)?
